Items tagged with Research and development
Closing the TB funding gap (post)
It has been 25 years since tuberculosis was declared a global-health emergency. But while world leaders generally agree on the need to invest in solutions, surprisingly few new TB medicines are being developed.
G-Finder 2018 report: Neglected disease research and development: Reaching new heights (post)
Policy Cures Research released the G-Finder 2018 report analysing research and development (R&D) funding trends for 33 neglected diseases, including TB. According to the G-Finder 2018 executive summary, the report “provides an up-to-date analysis of how R&D investments are being allocated across diseases and product types, funding trends over time, and where the potential gaps lie.”
Call for contribution to the public consultation on the development of a global strategy for TB research and innovation (post)
21 March 2019 | Geneva:The World Health Organization (WHO) has produced a draft Global Strategy for Tuberculosis (TB) Research and Innovation (Global Strategy) for consideration by the World Health Assembly (WHA) at its 73rd session. The draft Global Strategy is now available online for comment.
Will new TB treatments reach those who need them most? (post)
MADRID — Pharma giant GlaxoSmithKline is pursuing new treatments for tuberculosis but insists it will need support from governments and funding agencies if it is to get them to patients in lower-income countries, the head of its global health unit, David Barros-Aguirre, told Devex.
“Dialogue” highlighted as way forward at closure of WHO Fair Pricing Forum (post)
WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines.
TB Alliance and Mylan announce global collaboration to commercialize investigational drug pretomanid as part of two regimens to treat TB (post)
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).
Drug price transparency: 10 countries back World Health Assembly resolution (post)
Ten countries, including five European Union (EU) member states, have now lined up in support of a landmark resolution to increase transparency of drug prices globally, which is expected to be a key focus of deliberations by WHO member states as they convene for the 72nd World Health Assembly (WHA), May 20-28 in Geneva.
Several developed countries want to “derail” transparency resolution – civil society groups say (post)
More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs.
Report of the High-level consultation on accelerating the development of the M72/AS01E TB vaccine candidate (post)
The High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate was convened by the World Health Organization on 5 April 2019.
Health Policy Watch makes latest text of WHO transparency resolution open access (post)
Health Policy Watch is publishing in an open-access format the latest draft of the World Health Assembly resolution on transparency of drug costs. The new draft, now available to all, reflects changes from the 10 May closed-door informal negotiations at the WHO, and shows progress toward compromise among member states.
Page 11 of 28 · Total posts: 0
←First 10 11 12 Last→